Search
What are you looking for?
Start main content

Press Releases

Press Releases

https://www.med.cuhk.edu.hk/press-releases/cuhk-discovers-a-blood-regulator-linked-to-tumour-microenvironment-formation-sparking-a-new-therapeutic-target-for-lung-cancer
https://www.med.cuhk.edu.hk/press-releases/cuhk-discovers-a-blood-regulator-linked-to-tumour-microenvironment-formation-sparking-a-new-therapeutic-target-for-lung-cancer

CUHK discovers a blood regulator linked to tumour microenvironment formation, sparking a new therapeutic target for lung cancer

lung caner study

CU Medicine has discovered that lung cancer can utilise a blood formation regulator Runx1to construct the tumour microenvironment. (From left) Professor To Ka-fai, Assistant Professor Professor Patrick Tang, Postdoctoral Fellow Dr Philip Tang Chiu-tsun, and PhD student Mr Max Chan Kam-kwan.

Lung cancer is the leading cause of cancer deaths in Hong Kong and worldwide, but there is still an unmet clinical need for effective therapeutic strategies. A new study from The Chinese University of Hong Kong (CUHK)’s Faculty of Medicine (CU Medicine) has discovered that lung cancer can utilise a blood formation regulator to construct tumour microenvironment. The team validated the translational potential and safety of this new target on experimental models, demonstrating its clinical relevance for lung cancer. The findings have been published in the leading international scientific journal Advanced Science.

Seeking new hope for lung cancer treatment from the tumour microenvironment

 

Cancer cells are heterogeneous and therefore difficult to eliminate completely. Effective cancer treatment remains a major clinical challenge.

 

Professor Patrick Tang Ming-kuen, Assistant Professor in the Department of Anatomical and Cellular Pathology at CU Medicine, said, “Increasing evidence demonstrates that the tumour microenvironment – that is, non-cancerous cells in tumour tissue – is important for cancer growth and metastasis. In contrast to cancer cells, tumour microenvironment is not heterogeneous, making them an ideal target for cancer therapy. Nowadays, advances in single-cell bioinformatics allow us to better understand the tumour microenvironment, so that some cancer-promoting mechanisms that can only be observed at the single-cell level can be discovered which may be useful for cancer treatment.”

 

In 2022, the same team reported an important phenomenon “Macrophage-Myofibroblast Transition” (MMT) for the formation of tumour microenvironment. This mechanism causes the anti-cancer immune cells “macrophages” to be further transformed into cancer-promoting myofibroblasts in lung cancer due to long-term overactivation. The underlying mechanism is still largely unclear.

 

Dr Philip Tang Chiu-tsun, Postdoctoral Fellow in the Department of Anatomical and Cellular Pathology at CU Medicine, explained, “Here, we attempted to investigate the underlying regulation at the single cell level and unexpectedly discovered that a hematopoietic regulatory factor Runx1 (full name Runt-related transcription factor 1) is critical for promoting patients’ macrophages undergoing MMT, which may represent an effective target for lung cancer treatment.”

 

Clinical significance of Runx1 as a redundant hematopoietic pathway in cancer therapy

 

Professor Patrick Tang commented, “Since Runx1 plays an important role in blood formation, inhibiting Runx1 may affect hematopoietic function, leading to doubts about its clinical value in cancer treatment. Fortunately, a new study (Blood Adv (2021) 5 (23): 4949–4962) showed that zebrafish lacking Runx1 can still maintain normal haematopoiesis through other pathways.” Mr Max Chan Kam-kwan, PhD student in the same department, added, “Encouragingly, genetic and pharmaceutical inhibition of Runx1 effectively inhibited MMT and tumour growth in mice, where no side effects were detected.”

 

Professor To Ka-fai, Professor in the Department of Anatomical and Cellular Pathology, highlights the clinical importance of this study: “The preclinical data generated from this work will serve as an important rationale for further transforming tumour microenvironment discoveries into clinical applications. It may eventually develop into an effective solution to end cancer via targeting MMT.”

 

Study graphic

The findings have been published in the leading international scientific journal Advanced Science

This study was supported by the Research Grants Council of Hong Kong, the Health and Medical Research Fund, the State Key Laboratory of Translational Oncology, and CU Medicine’s Passion for Perfection scheme and Faculty Innovation Award. Other key participants in the study included Professors Calvin Ng Sze-hang, Leung Kam-tong and Lan Hui-yao from CU Medicine. 

 

The original study can be accessed here: https://onlinelibrary.wiley.com/doi/10.1002/advs.202470006

 

More Press Releases

 CU Medicine uncovers the key for immune suppression in lung cancer Translating blood’s hidden gem “Neutrophil” into a new generation anti-cancer therapy

CU Medicine uncovers the key for immune suppression in lung cancer Translating blood’s hidden gem “Neutrophil” into a new generation anti-cancer therapy

Research
CUHK unlocks the secret of cancer pain  Identifying a new therapeutic key to ending the sorrow

CUHK unlocks the secret of cancer pain Identifying a new therapeutic key to ending the sorrow

Research
CUHK dissects lung carcinoma at single-cell resolution uncovering a new mechanism for tumour formation

CUHK dissects lung carcinoma at single-cell resolution uncovering a new mechanism for tumour formation

Research
CUHK Uncovers How Immune Cells Turn Bad A New Hope for Kidney Patients

CUHK Uncovers How Immune Cells Turn Bad A New Hope for Kidney Patients

Research
CUHK Uncovers Novel Immune Escape Mechanism of Cancer Opening Up New Direction for Cancer Immunotherapy

CUHK Uncovers Novel Immune Escape Mechanism of Cancer Opening Up New Direction for Cancer Immunotherapy

Research
CUHK Uncovers a New Strategy to Turn “Cold” Liver Tumour “Hot” Leading to an Effective and Durable Combined Immunotherapy

CUHK Uncovers a New Strategy to Turn “Cold” Liver Tumour “Hot” Leading to an Effective and Durable Combined Immunotherapy

Research
CUHK Unravels the Whole Genome of Nasopharyngeal Cancer A Great Leap Forward in Personalized Medicine Development

CUHK Unravels the Whole Genome of Nasopharyngeal Cancer A Great Leap Forward in Personalized Medicine Development

Research
CU Medicine developed an innovative mRNA drug for treatment of nasopharyngeal carcinoma

CU Medicine developed an innovative mRNA drug for treatment of nasopharyngeal carcinoma

Research
CUHK develops novel molecular classification of cancer-associated fibroblasts across multiple cancers, improving understanding for more targeted treatment

CUHK develops novel molecular classification of cancer-associated fibroblasts across multiple cancers, improving understanding for more targeted treatment

Research
International lung cancer study involving CU Medicine shows that a targeted therapy doubles the progression-free survival of advanced cancer patients, compared to standard treatment

International lung cancer study involving CU Medicine shows that a targeted therapy doubles the progression-free survival of advanced cancer patients, compared to standard treatment

Research
CU Medicine establishes an internationally accredited biobank:  A prerequisite for Hong Kong to be the hub for new drug development in the Greater Bay Area

CU Medicine establishes an internationally accredited biobank: A prerequisite for Hong Kong to be the hub for new drug development in the Greater Bay Area

Milestone
CUHK performs world’s first robotic-assisted bronchoscopic  microwave ablation of lung metastases

CUHK performs world’s first robotic-assisted bronchoscopic microwave ablation of lung metastases

Surgical advancement
International lung cancer study involving CU Medicine reveals that combination of immune drugs and chemotherapy represents new treatment regime for metastatic NSCLC patients

International lung cancer study involving CU Medicine reveals that combination of immune drugs and chemotherapy represents new treatment regime for metastatic NSCLC patients

Research
CUHK co-leads global lung cancer study  Supporting lorlatinib as first-line treatment option for ALK-positive advanced NSCLC patients

CUHK co-leads global lung cancer study Supporting lorlatinib as first-line treatment option for ALK-positive advanced NSCLC patients

Research
Study by CUHK medical students identifies STK3 kinase as a driver in gastric cancer

Study by CUHK medical students identifies STK3 kinase as a driver in gastric cancer

Education
CU Medicine collaborates with South Korean institutes to develop  an AI-powered analytic tool for lung cancer immunotherapy

CU Medicine collaborates with South Korean institutes to develop an AI-powered analytic tool for lung cancer immunotherapy

Research
CUHK performs the first hybrid operating room robotic-assisted bronchoscopy procedure outside the US

CUHK performs the first hybrid operating room robotic-assisted bronchoscopy procedure outside the US

Surgical advancement
CU Medicine finds Eastern Asia’s lung cancer incidence and mortality highest in the world

CU Medicine finds Eastern Asia’s lung cancer incidence and mortality highest in the world

Research
Professor Tony Mok Recognised as a Giant of Cancer Care  for His Remarkable Contribution in Advancing Global Healthcare in Lung Cancer

Professor Tony Mok Recognised as a Giant of Cancer Care for His Remarkable Contribution in Advancing Global Healthcare in Lung Cancer

Awards and honors
CUHK to Commence the Next-Generation Clinical Trials of CAR-T Cell Therapy for Haematological Malignancy

CUHK to Commence the Next-Generation Clinical Trials of CAR-T Cell Therapy for Haematological Malignancy

Research
CUHK Successfully Conducts Asia-Pacific’s First Hybrid Operating Room Non-invasive Bronchoscopic Microwave Ablation to Treat Lung Cancer

CUHK Successfully Conducts Asia-Pacific’s First Hybrid Operating Room Non-invasive Bronchoscopic Microwave Ablation to Treat Lung Cancer

Surgical advancement
Professor Tony MOK Honoured with the ESMO Lifetime Achievement Award Recognising His Global Leadership in Defining Lung Cancer Treatment Standard

Professor Tony MOK Honoured with the ESMO Lifetime Achievement Award Recognising His Global Leadership in Defining Lung Cancer Treatment Standard

Awards and honors
CUHK-led Global Study Sees Improvement in Overall Survival in Patients with Advanced Lung Cancer

CUHK-led Global Study Sees Improvement in Overall Survival in Patients with Advanced Lung Cancer

Research
CUHK Pioneers Early Lung Cancer Treatment with Hybrid Operating Room Image Guided Electromagnetic Navigation Bronchoscopy

CUHK Pioneers Early Lung Cancer Treatment with Hybrid Operating Room Image Guided Electromagnetic Navigation Bronchoscopy

Surgical advancement
CUHK Research Receives Recognitions by Top Medical Journals

CUHK Research Receives Recognitions by Top Medical Journals

Awards and honors
CUHK-led Research Confirms Novel Targeted Therapy Doubles the Effectiveness of Current Standard Treatment for ALK-Positive Lung Cancer

CUHK-led Research Confirms Novel Targeted Therapy Doubles the Effectiveness of Current Standard Treatment for ALK-Positive Lung Cancer

Research
CUHK Leads a Multinational Study that Finds New Treatment Paradigm of Mutated Lung Cancer

CUHK Leads a Multinational Study that Finds New Treatment Paradigm of Mutated Lung Cancer

Research
CUHK Joint Research Sets a New Global Direction for Lung Cancer Treatment Molecular Targeted Therapy Proved more Effective in Treating Patients with ALK-Positive Lung Cancer

CUHK Joint Research Sets a New Global Direction for Lung Cancer Treatment Molecular Targeted Therapy Proved more Effective in Treating Patients with ALK-Positive Lung Cancer

Research
Inaugural Lecture of Li Shu Fan Medical Foundation Professorship in Clinical Oncology by Prof. Tony Mok 'Declaration of War Against Lung Cancer'

Inaugural Lecture of Li Shu Fan Medical Foundation Professorship in Clinical Oncology by Prof. Tony Mok 'Declaration of War Against Lung Cancer'

Symposium

Our Expert List

Many experts under the Faculty of Medicine are available for media interview.
Please click here for the expert list or contact us.